Table II.
Estimated Difference in Adjusted Mean Change From Baseline in MSSBP by Treatment Strategy in Diabetic and Nondiabetic Subgroups of Val‐MARC, VALOR, and VELOCITY
| Study | Strategy | LSM Change From Baseline in MSSBP (mm Hg), Diabetic Patients | LSM Change From Baseline in MSSBP (mm Hg), Nondiabetic Patients | Mean Difference, Diabetics vs Nondiabetics | 95% CI for Mean Difference |
|---|---|---|---|---|---|
| VALOR (week 8) | Combination therapy | −30.6 | −27.7 | −2.8 | −7.0 to 1.3 |
| Monotherapy | −16.4 | −20.9 | 4.6 | −1.2 to 10.3 | |
| Val‐MARC (week 6) | Combination therapy | −24.4 | −24.8 | 0.3 | −3.9 to 4.6 |
| Monotherapy | −16.6 | −17.9 | 1.4 | −2.3 to 5.0 | |
| VELOCITY (week 4) | Combination therapy (high)a | −24.2 | −26.2 | 2.0 | −3.1 to 7.1 |
| Combination therapy (low)b | −21.5 | −21.6 | 0.1 | −5.0 to 5.1 | |
| Monotherapy | −14.6 | −15.2 | 0.6 | −5.1 to 6.2 |
Abbreviations: CI, confidence interval; LSM, least‐squares mean; MSSBP, mean sitting systolic blood pressure. a160/12.5→160/25 mg; b160/0→160/12.5 mg. See text for study name expansions.